Skip to main content

Medicxi — Portfolio

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

43
Companies
$2.2B
Total invested
$61.4M
Avg. check
13
Industries
Biotechnology 21Health Care 8Medical 8Therapeutics 8Life Science 7Pharmaceutical 6+7 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 1–24 of 43
Vicebio
September 2024

Vicebio is a biopharmaceutical company developing next-generation respiratory virus vaccines using the Molecular Clamp technology.

Biotechnology · London$100.0M Series B
Levicept
September 2021

Levicept develops biological agent for the treatment of chronic pain.

Biopharma · Sandwich$47.8M Series B
Versanis Bio
August 2021

Versanis Bio discovers and develops medicines that address medical conditions prevalent in older adults.

Biotechnology · Oakland$70.0M Series A
Vaderis Therapeutics
August 2026

Vaderis Therapeutics is a clinical-stage biotechnology company developing targeted therapies for rare vascular diseases.

Biotechnology · Basel$152.0M Series B
Sydnexis
August 2021

Sydnexis is engaged in the development of a proprietary treatment for pediatric progressive myopia.

Manufacturing · Del Mar$45.0M Series B
Fore Biotherapeutics
July 2026

Fore Biotherapeutics is a precision oncology company specializing in cancer therapies guided by functional genomics.

Biotechnology · Philadelphia$67.4M Series D
MiroBio
June 2022

MiroBio is Harnessing the natural control mechanisms of the immune system.

Biotechnology · Oxford$97.0M Series B
Aldena Therapeutics
June 2025

Aldena Therapeutics is a private biotech startup that invented siRNA-based treatments for dermatological conditions.

Biotechnology · Boston$656K Grant
Curevo
March 2025

Curevo is a clinical-stage biotechnology company developing next-generation, non-mRNA vaccines for infectious diseases.

Biopharma · Bothell$110.0M Series B
Altesa
February 2026

Altesa is a clinical-stage biopharmaceutical company dedicated to accelerating the development of new treatments

Biotechnology · College Park$75.0M Series B
Alys Pharmaceuticals
February 2024

Alys Pharmaceuticals is a biopharmaceutical company focused on developing immuno-dermatology treatments.

Biotechnology · Boston$100.0M Seed
Diasome Pharmaceuticals
June 2023

Diasome Pharmaceuticals is a clinical-stage diabetes therapeutics company that designs and develops insulin-based therapies.

Biotechnology · Cleveland$9.0M Venture - Series Unknown
Rivus Pharmaceuticals
January 2025

Rivus Pharmaceuticals operates as a biopharmaceutical company dedicated to improving cardio-metabolic health.

Biotechnology · Charlottesville$57.0M Venture - Series Unknown
Ethyreal Bio
January 2026

Ethyreal Bio is a biotechnology startup developing precision therapies for autoimmune thyroid disorders.

Biotechnology · Cambridge$60.0M Series B
SynOx Therapeutics
October 2024

SynOx Therapeutics is a biotechnology research company that focused on developing the treatment of diffuse tenosynovial giant cell tumors.

Biotechnology · Dublin$92.0M Series B
Vaxcyte
January 2026

Vaxcyte focuses on developing vaccines designed to prevent or treat some of the most common and deadly infectious diseases worldwide.

Biopharma · San Carlos$632.5M Post Ipo Equity
D3 Bio
December 2025

D3 Bio is a biotechnology company focusing on the development and registration of medicines.

Biotechnology · Wuxi Shi$108.0M Series B
New Amsterdam Pharma
December 2024

New Amsterdam is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases.

Biotechnology · Naarden$452.6M Post Ipo Equity
ProfoundBio
February 2024

ProfoundBio is a developer of targeted therapeutics intended for patients with cancer.

Biotechnology · Seattle$112.0M Series B
Kurome Therapeutics
June 2021

Kurome Therapeutics is a preclinical stage company focused on subverting cancer's ability to evade therapy.

Biotechnology · Cincinnati$15.0M Series A
Janpix
October 2020

Janpix operates as an oncology-focused startup.

App Discovery · Cambridge$10.0M Series B
Alderaan Biotechnology
January 2020

Alderaan is a biotechnology company.

Biotechnology · Paris$20.6M Series A

Where Medicxi invests

Biotechnology21
Health Care8
Medical8
Therapeutics8
Life Science7
Pharmaceutical6

About Medicxi's portfolio

How many companies has Medicxi invested in?▸

Medicxi has invested in 43 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does Medicxi invest in?▸

Medicxi's top investment sectors include Biotechnology, Health Care, Medical, Therapeutics, Life Science. The firm invests across 13 different industry categories.

What is Medicxi's largest investment?▸

Among tracked funding rounds, Vaxcyte received $632.5M in a Post Ipo Equity round. Medicxi's total known invested capital is $2.2B.

What is the average investment size for Medicxi?▸

Medicxi's average investment size is $61.4M across its portfolio of 43 companies.

What are Medicxi's most recent investments?▸

Recent Medicxi portfolio additions include Vicebio, Levicept, Versanis Bio, Vaderis Therapeutics, Sydnexis. These companies were founded in 2020 or later.

Reach the founders behind these 43 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →